CA2339368A1 - Inhibition de la 3$g(a)-hydroxysteroid-deshydrogenase de type 3 - Google Patents

Inhibition de la 3$g(a)-hydroxysteroid-deshydrogenase de type 3 Download PDF

Info

Publication number
CA2339368A1
CA2339368A1 CA002339368A CA2339368A CA2339368A1 CA 2339368 A1 CA2339368 A1 CA 2339368A1 CA 002339368 A CA002339368 A CA 002339368A CA 2339368 A CA2339368 A CA 2339368A CA 2339368 A1 CA2339368 A1 CA 2339368A1
Authority
CA
Canada
Prior art keywords
alpha
inhibitor
beta
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002339368A
Other languages
English (en)
Inventor
Fernand Labrie
Yves Merand
Sylvain Gauthier
Louis Provencher
Van Luu-The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorecherche Inc filed Critical Endorecherche Inc
Publication of CA2339368A1 publication Critical patent/CA2339368A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur de nouveaux procédés de traitement et/ou inhibition du développement du cancer de la prostate, de l'hyperplasie prostatique bénigne, des prostatites, de l'acné, de la séborrhée, de l'hirsutisme ou de l'alopécie masculine à l'aide de 3.alpha.-hydroxystéroid-déshydrogénase de type 3 seule ou combinée à d'autres produits pharmaceutiques actifs tels que les inhibiteurs 17.beta.-hydroxystéroid-déshydrogénase de type 5. L'invention porte également sur de nouveaux inhibiteurs et produits pharmaceutiques.
CA002339368A 1998-08-07 1999-08-06 Inhibition de la 3$g(a)-hydroxysteroid-deshydrogenase de type 3 Abandoned CA2339368A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9562398P 1998-08-07 1998-08-07
US60/095,623 1998-08-07
PCT/CA1999/000724 WO2000007576A2 (fr) 1998-08-07 1999-08-06 INHIBITION DE LA 3$G(a)-HYDROXYSTEROID-DESHYDROGENASE DE TYPE 3

Publications (1)

Publication Number Publication Date
CA2339368A1 true CA2339368A1 (fr) 2000-02-17

Family

ID=22252842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002339368A Abandoned CA2339368A1 (fr) 1998-08-07 1999-08-06 Inhibition de la 3$g(a)-hydroxysteroid-deshydrogenase de type 3

Country Status (9)

Country Link
EP (1) EP1102582A2 (fr)
JP (1) JP2002522380A (fr)
CN (1) CN1322130A (fr)
AR (1) AR021757A1 (fr)
AU (1) AU5144999A (fr)
CA (1) CA2339368A1 (fr)
ID (1) ID28791A (fr)
NO (1) NO20010651L (fr)
WO (1) WO2000007576A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
WO2008124922A1 (fr) * 2007-04-12 2008-10-23 Endorecherche, Inc. Stéroïdes 17-alpha-substitués utilisés comme anti-androgènes systémiques et modulateurs sélectifs du récepteur de l'androgène

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
EP1321146A3 (fr) * 1998-03-11 2004-06-02 Endorecherche Inc. Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6891953B1 (en) 2000-06-27 2005-05-10 Microsoft Corporation Method and system for binding enhanced software features to a persona
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
AU2001288386B2 (en) * 2000-11-27 2006-11-02 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
US6710037B2 (en) * 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
DE60239207D1 (de) * 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1574212A1 (fr) * 2001-11-29 2005-09-14 GTX Inc. Prévention et traitement des maladies induite par la privation d'androgène
WO2005089256A2 (fr) 2004-03-12 2005-09-29 Entremed, Inc. Agents anti-angiogeniques
US7419972B2 (en) 2004-07-02 2008-09-02 Schering Ag 2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
DE102004032674A1 (de) * 2004-07-02 2006-01-26 Schering Ag Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
AU2008292420A1 (en) * 2007-08-31 2009-03-05 Astellas Pharma Inc. Piperidine derivative
CN101698834B (zh) * 2009-09-08 2012-05-23 北京利德曼生化股份有限公司 3α-羟基类固醇脱氢酶及其核苷酸序列、重组载体、重组宿主细胞和试剂盒
PE20150353A1 (es) * 2012-07-10 2015-03-28 Bayer Pharma AG Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
KR20150118153A (ko) * 2013-02-21 2015-10-21 바이엘 파마 악티엔게젤샤프트 17.베타.-히드록시스테로이드 데히드로게나제 (akr1 c3)의 억제를 위한 에스트라-1,3,5(10),16-테트라엔-3-카르복스아미드
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
CN104873525A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂及其药用组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3562260A (en) * 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US4340602A (en) * 1978-10-18 1982-07-20 Wayne State University Compositions inhibiting estrogen sulfotransferase activity
AU556749B2 (en) * 1983-02-22 1986-11-20 Liehr, J.G. Pharmaceutical compositions of 2-fluoroestradiol
US4568673A (en) * 1984-03-20 1986-02-04 Wayne State University Compositions inhibiting murine MXT ductal carcinoma
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
BR9908592A (pt) * 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
WO2008124922A1 (fr) * 2007-04-12 2008-10-23 Endorecherche, Inc. Stéroïdes 17-alpha-substitués utilisés comme anti-androgènes systémiques et modulateurs sélectifs du récepteur de l'androgène
AU2008238559B2 (en) * 2007-04-12 2012-05-31 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators

Also Published As

Publication number Publication date
AR021757A1 (es) 2002-08-07
NO20010651D0 (no) 2001-02-07
AU5144999A (en) 2000-02-28
NO20010651L (no) 2001-04-05
ID28791A (id) 2001-07-05
JP2002522380A (ja) 2002-07-23
WO2000007576A3 (fr) 2000-03-30
WO2000007576A2 (fr) 2000-02-17
CN1322130A (zh) 2001-11-14
EP1102582A2 (fr) 2001-05-30

Similar Documents

Publication Publication Date Title
CA2339368A1 (fr) Inhibition de la 3$g(a)-hydroxysteroid-deshydrogenase de type 3
US6541463B1 (en) Inhibitors of type 5 and type 3 17β-hydroxysteroid dehydrogenase and methods for their use
Aggarwal et al. An overview on 5α-reductase inhibitors
JP3581802B2 (ja) ステロイドスルファターゼインヒビター
US5763432A (en) Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
Banday et al. Steroidal pyrazolines and pyrazoles as potential 5α-reductase inhibitors: Synthesis and biological evaluation
JP2001510471A (ja) アンドロゲン合成インヒビター
EP0646007B1 (fr) NOUVELLES 4-AZA-5$g(a)-ANDROSTAN-ONES SUBSTITUEES EN POSITION 17$g(b), SATUREES ET DELTA-17 ET DELTA-20 OLEFINIQUES ET SATUREES UTILISEES COMME INHIBITEURS DE 5$g(a)-REDUCTASE
EP3013846B1 (fr) Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase
US5264427A (en) 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
JP2014094952A (ja) 局所活性「ソフト」抗アンドロゲン剤
CA2564963A1 (fr) Promedicaments steroides a effet androgene
US10265329B2 (en) Altering steroid metabolism for treatment of steroid-dependent disease
Arellano et al. New ester derivatives of dehydroepiandrosterone as 5α-reductase inhibitors
JP5290189B2 (ja) ６−アルコキシアルキルエストラジオール誘導体およびその使用
MXPA01001405A (en) INHIBITION OF TYPE 3 3&agr;-HYDROXYSTEROID DEHYDROGENASE
JPH06510982A (ja) 抗テストステロン化合物およびその使用方法
EP1321146A2 (fr) Inhibiteurs de la 17beta-hydroxysteroide deshydrogénase du type 5 et du type 3 ainsi que leurs méthodes d'utilisation
AU2004200173A1 (en) Inhibitors of Type 5 and Type 3 17B-Hydroxysteroid Dehydrogenase and Methods for Their Use
AU2017276477A1 (en) 15β-substituted estrone derivatives as selective inhibitors of 17β-hydroxysteoid-dehydrogenases, method of preparation and use thereof
Haidar et al. 5.7 enzyme inhibitor examples for the treatment of prostate tumor
Weintraub et al. 4-Amino-17β-(Cyclopropyloxy) androst-4-en-3-one, 4-Amino-17β-(Cyclopropylamino) androst-4-en-3-one and Related Compounds as C17, 20-Lyase and 5α-Reductase Inhibitors
PH26838A (en) Aromatic steroid 5-alpha reductase inhibitors

Legal Events

Date Code Title Description
FZDE Dead